Добірка наукової літератури з теми "Voies oncogènes"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Voies oncogènes".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Voies oncogènes":
Mbimenyuy, C. M., J. F. Cho, A. E. Mugyia, G. M. Ikomey, D. M. Tebit, and D. A. Nota. "Comparative HPV genotype distribution among women with normal and abnormal cervical cytology in Yaoundé, Cameroon." African Journal of Clinical and Experimental Microbiology 24, no. 2 (April 18, 2023): 158–67. http://dx.doi.org/10.4314/ajcem.v24i2.5.
Дисертації з теми "Voies oncogènes":
Bachet, Jean-Baptiste. "Récepteurs tyrosine-kinase, voies de signalisation et tumeurs digestives." Versailles-St Quentin en Yvelines, 2013. http://www.theses.fr/2013VERS0019.
Receptor tyrosine kinases (RTKs) are pro-oncogenes involved in the pathogenesis of many gastrointestinal tumors. We conducted several studies of translational and basic research on the RTK KIT and the gastrointestinal stromal tumors (GISTs). GISTs with delWK557-558 and those with a deletion carrying the two tyrosine residues in KIT exon 11 had the same prognosis. Homozygous GISTs appear more often malignant than heterozygous GISTs. We then reported that homozygous GISTs may be secondary to loss of heterozygosity without loss of genetic material. From cell lines, we demonstrated that the biology of KIT in heterozygous cells was closer to that hemizygous unmutated KIT cells that hemizygous mutated KIT. The hemizygous/heterozygous status on the one hand and the loss or non-tyrosine residues of the KIT exon 11 on the other hand were associated with specific expression profiles of mRNA and miRNAs. Finally, we have described three families with a germline mutation in exon 13 of KIT, and we proposed recommendations for their management
Cassinat, Bruno. "Etude de l'interconnexion des voies de signalisation du G-CSF avec la voie des récepteurs nucléaires retinoïques : identification de voies synergiques et application à la différenciation de cellules leucémiques." Paris 7, 2012. http://www.theses.fr/2012PA077045.
The identification of RARa gene rearrangement as the molecular origin of Acute Promyelocytic Leukemia (APL) led to the first targeted therapy aiming at reinducing normal differentiation of tumour cells using retinoic Acid (RA). Because we previously identified a level of heterogeneity in in vitro response of patients' cells to the RA induced differentiation which was correlated to the heterogeneity in clinical response, we developed several studies: -we collaborated to a study which allowed to identify certain mutations of the PML-RARα gene in APL patients with an adverse prognostic. We have also shown in another study that the minimal residual disease analysis using quantitative RT-PCR allowed to better identify patients that will relapse. We also demonstrated that a high frequency of Auer rods in APL cells at diagnosis is correlated to a poorer clinical outcome. -We have analysed whether extracellular signalling of 2 different origins (membrane signalling induced by the G-CSF and nuclear signalling induced by RA) may be interconnected and become synergistic to induce the differentiation of APL cells. In a model of APL cells resistant to the differentiation effect of RA we demonstrated that ERK1/2 pathway can restore transcriptional activation by RA via RARα, CBP/P300 and acetylated histone H3 recruitment on RA target gene promoters
Mahé, Mélanie. "Caractérisation des voies de signalisation des oncogènes FGFR3 muté et FGFR3-TACC3 dans les carcinomes de vessie." Thesis, Paris 11, 2015. http://www.theses.fr/2015PA11T020/document.
Bladder cancer progression can be divided in two main pathways. The pathway of In Situ Carcinoma (CIS) which progress through an invasion of the basement membrane and then the muscle and the pathway of Ta papillary tumors which change little but recur frequently after tumor resection. Approximately 65% of Ta papillary tumors harboring a FGFR3 mutation and recently FGFR3-TACC3 fusion proteins have been observed in bladder tumors (about 10% of bladder tumors). The oncogenic role of the mutated FGFR3 receptor and of the FGFR3-TACC3 fusion protein has been demonstrated in vivo and in vitro. However signaling pathways activated by the mutated FGFR3 receptor or by the FGFR3-TACC3 fusion protein are currently poorly characterized.In this context, two approaches have been developed to characterize these signaling pathways. The first is based on the study of p38, AKT and ERK1/2 phosphorylation by the mutated receptor (S249C) or the wild type receptor in the NIH3T3 fibroblastic cell line. This study allowed identifying p38 and AKT as activated by the mutated FGFR3 receptor. Moreover, activation of p38 and AKT by the mutated receptor is critical for cell transformation. Study of the activation of these two signaling has been realized in human bladder cancer cell lines endogenously expressing the mutated FGFR3 receptor or the FGFR3-TACC3 fusion protein. Moreover, we showed that p38 and AKT are involved in the maintenance of a FGFR3/MYC feedback positive loop: FGFR3 activation induce MYC over expression which in turns promotes FGFR3 expression. The second approach is based on a study whose aim was to identify FGFR3 proteins partners by mass spectrometry after a FGFR3 immunoprecipitation, which has been previously realized in the lab. Data analyze led to the obtaining of a list of 60 proteins identified has FGFR3 protein partners with a high confidence. Construction of a FGFR3 network with this list was not possible (too little interactions existing between these proteins), so we developed an algorithm (PEPPER) in collaboration with a student in bioinformatics in the lab, Remy Nicolle, to propose a FGFR3 signaling network.The two approaches developed during this thesis allowed us to better characterize the FGFR3 signaling pathways. Identification of a FGFR3/MYC feedback loop allowed us to better understand why the altered FGFR3 has oncogenic properties and to propose p38 and AKT as news promising therapeutic targets, to treat human bladder tumors harboring the altered FGFR3 receptor. Construction of the FGFR3 signaling network with the algorithme PEPPER give an overview of the FGFR3 signaling pathways and open new tracks to explore
Lemaire, Frédéric. "Caractérisation de l'expression génique des tumeurs des voies aérodigestives supérieures : perspectives diagnostiques et thérapeutiques." Paris, Institut national d'agronomie de Paris Grignon, 2004. https://pastel.archives-ouvertes.fr/pastel-00000629.
Dormoy, Valérian. "Du développement au cancer : implication des voies néphrogéniques dans la croissance du carcinome à cellules rénales humain." Strasbourg, 2010. https://publication-theses.unistra.fr/public/theses_doctorat/2010/DORMOY_Valerian_2010.pdf.
Kidney cancer remains resistant to therapies. Several genes play essential roles in human development, particularly during nephrogenesis. The concept suggesting that these actors could be expressed by cancer cells has recently emerged. In our studies, we investigated if cancerogenesis and tumor growth in renal cell carcinoma are linked to the developmental pathways. For this purpose, we focussed particularly on the developmental sonic hedgehog pathway, and then on the nephrogenic transcription factor Lim1. The expression of the SHH pathway and of Lim1 in RCC were analysed on RCC cell lines and tumors from human RCC. The proliferative and apoptosis effects of the SHH pathway and of Lim1 on kidney cancer cells were evaluated in vitro. Their involvement in kidney cancer cells migration and invasion were also studied, as well as their interaction with oncogenic pathways by Western blot. Focussed on the description of therapeutical innovation, we used xenografted mice to analyze the effects of the inhibition of these developmental pathways/markers in vivo. Our results demonstrate that the SHH pathway and Lim1 are reexpressed in RCC cell lines and in human tumors. The inhibition of these actors led to a radical decrease of cancer cells proliferation and migration. In vivo, targeting these pathways/markers, that we showed to participate to the regulation of oncogenic pathways, induced a decrease of tumor growth and even marked tumor regression. The developmental pathways implicated in RCC growth could constitute an important therapeutical innovation in the treatment of this cancer, and allow us to put an additional piece in the molecular puzzle of molecular cancer mechanisms
Denoyelle, Christophe. "La protéine RhoA et ses voies de signalisation : Perspectives d'une nouvelle stratégie thérapeutique dans le traitement des cancers du sein agressifs." Rouen, 2003. http://www.theses.fr/2003ROUES005.
We have shown that HMG-CoA reductase inhibitors (statins) currently used in the treatment of hypercholesterolemia prevent the formation of geranylgeranylpyrophosphate (GGPP) and reduce the membrane localisation (=activation) of RhoA leading to the inhibition of cell proliferation and invasion of aggressive breast cancer cells in vitro and in vivo. Other mechanisms involved in the anticancer activity of statins (action on CDKi, proteases, Wnt-5a) were identified at molecular level using microarray. Finally, we have shown that bisphosphonates, which have a biodisponibility higher than statin, prevent also the membrane localisation of RhoA leading to the reduction of both cell invasion and chemotactic effect of cancer cells. To conclude, the inhibition of RhoA cell signalling pathways seems to be a good strategy to fight aggressive cancers
Lemaire, Frédéric Jean Laurent. "Caractérisation de l'expression génique des tumeurs des voies aérodigestives supérieures: perspectives diagnostiques et thérapeutiques." Phd thesis, INAPG (AgroParisTech), 2004. http://pastel.archives-ouvertes.fr/pastel-00000629.
Goormachtigh, Gautier. "Etude de LMP1, oncogène majeur du virus d'Epstein-Barr : autorégulation de son expression par les effets antagonistes des voies de signalisation cellulaire JNK et NFkB." Lille 2, 2006. http://www.theses.fr/2006LIL2S011.
Lefevre, Gaëlle. "Identification des voies de signalisation participant à la tumorigénèse du mélanome choroïdien humain : implications thérapeutiques." Paris 7, 2004. http://www.theses.fr/2004PA077232.
Uveal melanoma is the most frequent intraocular primary tumour in adults. Although this cancer has a low incidence, its aggressive character as well as the absence of current satisfactory therapeutics to treat it lead us to study its physiopathology. We compared the expression levels of 120 proteins in both normal and tumoral melanocytes. We found that the ERK pathway was deregulated. We further confirmed that this deregulation was a major trait in uveal melanoma cells and that it was important for both the proliferation and transformation of these cells. We also identified two alterations responsible for the overactivation of the ERK pathway: 1) the presence of mutant B-Rafv599E and 2) the existence of an autocrine loop of activation by SCF/c-Kit. Inhibition of this latter with STI571 demonstrated promising in vitro results for future therapeutic application
Medyouf, Hind. "Identification et étude de voies moléculaires oncogéniques dans les lymphomes et leucémies lymphoïdes." Paris 7, 2007. http://www.theses.fr/2007PA077042.
In this study we were interested in evaluating the importance of calcineurin activation, a serine threonine phosphatase, in leukemia développement. We demonstrate that sustained calcineurin activation is observed in ail mouse models of T-cell malignancies tested among which, activated Notchl(ICN1)- or TEL-JAK2-induced T-cell acute lymphoblastic leukemia (T-ALL). Thèse models are highly relevant to human malignancies. Indeed, deregulation of the JAK/STAT pathway has been reported in a number of ALL, and more recently, it has been shown that activating-mutations of Notchl are found in over 50% of T-ALL patients. We further show that in vivo inhibition of calcineurin activity in these two mouse models by CsA or Tacrolimus, two well known inhibitors of calcineurin currently used in human medicine as immunosuppressant, induced apoptosis of leukemic cells, rapid tumor clearance and signifïcantly prolonged mouse survival. Conversely, ectopic expression of a constitutively activated mutant of calcineurin favored leukemia progression, suggesting that calcineurin plays an intrinsic role in leukemic cells. We extended our study to human samples and human derived cell lines and show that similarly to what is observed in mouse models, ail samples obtained from aggressive B- and T-cell lymphoma patients, as well human leukemia (B and T) derived cell lines exhibit a sustained activation of calcineurin. In vitro treatment of these cell lines with CsA or Tacrolimus impaired their proliferation and induced apoptosis. From these results, we conclude that, calcineurin activation is critical for the maintenance of the leukemic phenotype in vivo, identifying this pathway as a potential novel therapeutic target in lymphoid malignancies